New oral drug trial offers hope for rare, Hard-to-Treat adrenal tumors
NCT ID NCT07282587
Summary
This study is testing an experimental oral medication called ONC206 for people with advanced pheochromocytoma or paraganglioma, rare tumors that often don't respond to standard treatments. About 90 participants will take the drug in different doses to see if it shrinks tumors and is safe. The goal is to control the disease and improve outcomes for patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
Mayo-Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
PENN
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Stanford
RECRUITINGPalo Alto, California, 94604, United States
-
U of Colorado
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
-
U of Michigan
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
-
UTAH
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.